Ground Breaking Advancements in the World of Diabetic Macular Edema
For the first time, patients who suffer from Diabetic Macular Edema (DME) have access to some real help. Lucentis, a FDA approved medicine, aids DME patients to rapidly regain their vision. This is a momentous time in the treatment for DME. Prior to Lucentis, the only option available was to stabilize current vision. Lucentis repairs the damage of the disease and actually improves vision.
OSM team’s goal is to provide the most advanced and complete eye treatment available anywhere to allow patients maximum benefit and eye health. OSM has the top, leading ophthalmologists trained in the most current, available FDA approved treatments and procedures. OSM offers revolutionary procedures such as new lens implants for the use of breakthrough laser technology for people suffering from both myopia and hyperopia and the latest advancements in astigmatism treatment.
The recent news on DME and diabetic eye care may be some of the most significant, inspiring news to date. OSM was one of the initial eye care practitioners in the Metro Detroit area to offer this ground breaking new treatment. OSM ophthalmologists are now able to fully restore vision that was once permanently damaged, truly a groundbreaking and extraordinary development in medicine. Genetech, the creators and manufacturers of Lucentis, made ophthalmic research history with Lucentis. Lucentis is a vital advancement in the on-going fight against diabetes-induced vision loss. OSM’s DME patients now receive treatment to restore their lost vision and are regaining a higher quality of life.
It is estimated that over half a million people enduring diabetes also struggle with DME, producing blurry vision and blindness. The effects of diabetes are presently the leading cause of blindness in adult Americans. Lucentis is the only medicine shown to help DME people regain sight. Approved by the FDA, it is the first advancement in treatment for this condition in 25 years. Schedule your appointment with OSM to recover the vision lost by Diabetic Macular Edema (DME).